
- Oncology NEWS International Vol 18 No 4
- Volume 18
- Issue 4
P53 mutation linked to advanced CRC in African-Americans
Researchers have identified a possible genetic cause for an increased risk for a more advanced form of colorectal cancer in blacks that leads to shorter survival, according to data published in Clinical Cancer Research (15:2406-2416, 2009).
Researchers have identified a possible genetic cause for an increased risk for a more advanced form of colorectal cancer in blacks that leads to shorter survival, according to data published in Clinical Cancer Research (15:2406-2416, 2009).
Upender Manne, PhD, and colleagues at the University of Alabama in Birmingham analyzed 137 colorectal adenocarcinomas from African-American patients and 236 colorectal adenocarcinomas from non-Hispanic whites. Researchers assessed these carcinomas for p53 mutations and genotyped for codon 72 polymorphisms.
Overall, whites and African-Americans had a similar rate of p53 mutations. However, the frequency of the Pro72 allele was higher in blacks (17%) compared with 7% among whites. By contrast, the Arg72 allele frequency was higher in whites (36%) than in African-Americans (19%).
Presence of the Pro72 allele in blacks was associated with a more than two-fold increase in mortality due to colorectal cancer (See “Minority groups protest CMS rejection of VC screening,” page 35).
Articles in this issue
over 16 years ago
Aureon launches prostate cancer predictorover 16 years ago
Ascenta Therapeutics cements treatment potential of AT-101over 16 years ago
Pathwork tissue test passes muster in multi-center investigationover 16 years ago
Hologic nabs approval for two new HPV testsover 16 years ago
Soy may protect against breast cancer in Asian womenover 16 years ago
Increased mortality risk cannot be excludedover 16 years ago
Research restores yoga’s role in active therapyover 16 years ago
MRS may eliminate need for invasive brain biopsyover 16 years ago
Who's Newsover 16 years ago
David Alberts: Survival of the fittestNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































